X0204 3 2012-01-01 0 0000806888 RESPONSE BIOMEDICAL CORP RBM 0001055951 ORBIMED ADVISORS LLC 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 0 0 1 0 0001055949 ISALY SAMUEL D 601 LEXINGTON AVENUE, 54TH FLOOR NEW YORK NY 10022 0 0 1 0 0001491569 OrbiMed Advisors Ltd 601 LEXINGTON AVENUE, 54TH FLOOR NEW YORK NY 10022 0 0 1 0 0001491520 ORBIMED ASIA GP, LP 601 LEXINGTON AVENUE, 54TH FLOOR NEW YORK NY 10022 0 0 1 0 0001432241 OrbiMed Capital GP III LLC 601 LEXINGTON AVENUE, 54TH FLOOR NEW YORK NY 10022 0 0 1 0 Common Stock 50793675 I See Footnotes Common Stock 483671 I See Footnotes Common Stock 30308282 I See Footnotes Warrant 0.0746 2011-12-30 2016-12-30 Common Stock 41707675 I See Footnotes Warrant 0.0746 2011-12-30 2016-12-30 Common Stock 397171 I See Footnotes Warrant 0.0746 2011-12-30 2016-12-30 Common Stock 24919282 I See Footnotes These shares of Common Stock of the Issuer ("Shares") and warrants to purchase Shares ("Warrants") are directly owned by OrbiMed Private Investments III, LP ("OPI III") and may be deemed to be indirectly beneficially owned by OrbiMed Capital GP III LLC ("OrbiMed Capital"), OrbiMed Advisors LLC ("OrbiMed Advisors") and Samuel D. Isaly ("Isaly"). OrbiMed Capital is the sole general partner of OPI III. OrbiMed Advisors, a registered adviser under the Investment Advisers Act of 1940, as amended, is the sole managing member of OrbiMed Capital. Pursuant to those relationships, OrbiMed Capital and OrbiMed Advisors have discretionary investment management authority with respect to the assets of OPI III. Such authority includes the power to vote and otherwise dispose of the securities held by OPI III. Isaly, a natural person, is the managing member of, and holder of a controlling interest in, OrbiMed Advisors. (Continued in 6 footnote) This report on Form 3 is jointly filed by OrbiMed Capital, OrbiMed Advisors, Isaly, OrbiMed Advisors Limited ("OrbiMed Limited") and OrbiMed Asia GP, L.P. ("OrbiMed Asia"). Each of the reporting persons disclaims beneficial ownership of the Shares and Warrants reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. The reporting persons have designated two representatives, currently David Wang, an employee of OrbiMed Advisors, and Peter Thompson, to serve on the Issuer's board of directors, each of whom disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the reporting persons are beneficial owners for the purpose of Section 16 of the Exchange Act, or for any other purpose. These Shares and Warrants are directly owned by OrbiMed Associates III, LP ("OA III") and may be deemed to be indirectly beneficially owned by OrbiMed Advisors and Isaly. OrbiMed Advisors is the sole general partner of OA III, and Isaly is the managing member of, and holder of a controlling interest in, OrbiMed Advisors. As a result, Isaly and OrbiMed Advisors share power to direct the vote and to direct the disposition of the securities held by OA III. These Shares and Warrants are directly owned by OrbiMed Asia Partners, L.P. ("OAP") and may be deemed to be indirectly beneficially owned by OrbiMed Asia and OrbiMed Limited. OrbiMed Asia is the sole general partner of OAP and OrbiMed Limited is the sole general partner of OrbiMed Asia. As a result, OrbiMed Asia has the power to direct the vote and to direct the disposition of the securities held by OAP and such power is exercised through OrbiMed Limited. Exercise prices shown are denominated in Canadian dollars. As a result, Isaly, OrbiMed Advisors and OrbiMed Capital share power to direct the disposition of the securities held by OPI III. The Reporting Persons are filing this form in connection with the Issuer transitioning from foreign private issuer to full reporting status, effective January 1, 2012. Samuel D. Isaly 2012-01-10